Drug-induced liver injury (DILI) is an acute inflammatory liver disease caused not only by prescription and over-the-counter medications but also by health foods and dietary supplements. Typically, DILI patients recover once the causative substance is identified and discontinued. In contrast, autoimmune hepatitis (AIH) results from the immune-mediated destruction of hepatocytes due to a breakdown of self-tolerance mechanisms. Patients presenting with acute-onset AIH often lack characteristic clinical features, such as autoantibodies, and require prompt steroid treatment to prevent progression to liver failure. Liver biopsy currently remains the gold standard to differentiate acute DILI from AIH; however, general pathologists face significant diagnostic challenges due to overlapping histopathological features. This study integrates pathology expertise with deep learning-based artificial intelligence (AI) to differentiate DILI from AIH using histopathological images. Our AI model demonstrates promising classification accuracy (Accuracy 74%, AUC 0.81). This paper presents a detailed pathological analysis alongside AI methods, discusses the current model performance and limitations, and proposes directions for future improvements.

The authors have declared no competing interest.

This work was supported by Grant-in-Aid for Scientific Research (B) and (C), Grant-in-Aid for Transformative Research Areas (A), from MEXT (22H05169, 22H05621, 24H00188, 24H01396, and 25K02282 to M.S., 23K06460 to K.H., and 24K14991 to K.I.).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Kanazawa University Ethics Committee (Approval No. 2016-317 (1985)).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The original whole-slide image data are derived from human patients and are not publicly available due to ethical and privacy restrictions. De-identified data may be made available from the corresponding author upon reasonable request and subject to approval by the institutional ethics committee.

The custom code newly generated in this study are available online (https://github.com/satouma7/Hepatitis).